![ADC Therapeutics SA Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/nyse/adct.png?tr=w-200)
ADC Therapeutics SA
NYSE:ADCT
![ADC Therapeutics SA Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/nyse/adct.png)
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Realty Income Corp
NYSE:O
|
Real Estate
|
US |
![]() |
Walt Disney Co
NYSE:DIS
|
Media
|
US |
![]() |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.4681
5.29
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
3M Co
NYSE:MMM
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Realty Income Corp
NYSE:O
|
US |
![]() |
Walt Disney Co
NYSE:DIS
|
US |
![]() |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nyse/adct.png)
Intrinsic Value
ADC Therapeutics SA is a clinical-stage biotechnology company. [ Read More ]
The intrinsic value of one
ADCT
stock under the Base Case scenario is
5.74
USD.
Compared to the current market price of 3.58 USD,
ADC Therapeutics SA
is
Undervalued by 38%.
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nyse/adct.png?tr=w-200)
Valuation Backtest
ADC Therapeutics SA
Run backtest to discover the historical profit from buying and selling
ADCT
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
ADC Therapeutics SA
Current Assets | 290.2m |
Cash & Short-Term Investments | 234.3m |
Receivables | 23.2m |
Other Current Assets | 32.7m |
Non-Current Assets | 17.8m |
Long-Term Investments | 930k |
PP&E | 15.8m |
Other Non-Current Assets | 986k |
Current Liabilities | 63m |
Accounts Payable | 14.3m |
Accrued Liabilities | 28.2m |
Other Current Liabilities | 20.5m |
Non-Current Liabilities | 439.4m |
Long-Term Debt | 423.2m |
Other Non-Current Liabilities | 16.2m |
Earnings Waterfall
ADC Therapeutics SA
Revenue
|
121.4m
USD
|
Cost of Revenue
|
-6m
USD
|
Gross Profit
|
115.4m
USD
|
Operating Expenses
|
-391.9m
USD
|
Operating Income
|
-276.5m
USD
|
Other Expenses
|
-105.1m
USD
|
Net Income
|
-381.6m
USD
|
Free Cash Flow Analysis
ADC Therapeutics SA
USD | |
Free Cash Flow | USD |
ADCT Profitability Score
Profitability Due Diligence
ADC Therapeutics SA's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nyse/adct.png)
Score
ADC Therapeutics SA's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
ADCT Solvency Score
Solvency Due Diligence
ADC Therapeutics SA's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nyse/adct.png)
Score
ADC Therapeutics SA's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ADCT Price Targets Summary
ADC Therapeutics SA
According to Wall Street analysts, the average 1-year price target for
ADCT
is 10.2 USD
with a low forecast of 8.08 USD and a high forecast of 13.65 USD.
Ownership
ADCT Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Price Appreciation
ADCT Price
ADC Therapeutics SA
Average Annual Return | -37.33% |
Standard Deviation of Annual Returns | 45.24% |
Max Drawdown | -99% |
Market Capitalization | 344.5m USD |
Shares Outstanding | 96 225 904 |
Percentage of Shares Shorted | 1.22% |
Company Profile
![ADC Therapeutics SA Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/nyse/adct.png?tr=w-200)
![ADC Therapeutics SA Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/nyse/adct.png?tr=w-200)
Country
Industry
Market Cap
Dividend Yield
Description
ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 312 full-time employees. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.
Contact
IPO
Employees
Officers
The intrinsic value of one
ADCT
stock under the Base Case scenario is
5.74
USD.
Compared to the current market price of 3.58 USD,
ADC Therapeutics SA
is
Undervalued by 38%.